Stock With Great Potential
Analyst says this stock could make quick strides with its unbelievable assets.
Learn more

RCE Insider Trading (Recce Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$50,003.25
Insider Selling (Last 12 Months): A$178,325.00

Recce Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Recce Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Recce Pharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/12/2020 01:00 AM ET

This chart shows the closing price history over time for RCE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Invest in Artificial Intelligence Before It Changes the World
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive. This is the golden age of investing in artificial intelligence!
Invest in this red-hot industry at pre-IPO prices.

Recce Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/21/2021Michele DiliziaInsiderSell175,000A$1.02A$178,325.00
6/16/2021James GrahamInsiderBuy47,850A$1.05A$50,003.25
7/9/2020James GrahamInsiderBuy389,712A$1.05A$409,197.60
12/19/2019James GrahamInsiderIssued192,307A$0.26A$49,999.82
8/7/2019Michele DiliziaInsiderSell277,000A$0.22A$60,109.00
See Full Table
High Arch Potential Stock
If you're looking for a hot new sector, watch this stock closely.
Click for ticker & full details

SEC Filings (Institutional Ownership Changes) for Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals logo
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti-infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Read More on Recce Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

630,087 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Recce Pharmaceuticals?

Recce Pharmaceuticals' top insider investors include:
  1. James Graham (Insider)
  2. Michele Dilizia (Insider)
Learn More about top insider investors at Recce Pharmaceuticals.
Crypto Millionaire: “Pay Attention to June 22nd”
Charlie Shrem is like the “Godfather of Cryptocurrencies”. He discovered Bitcoin when it was trading for $5. Ethereum at $109.

Binance at just $6. Cardano for 5 CENTS.

Today, he’s sharing the details of a $0.21 CENT crypto with Top 5 Potential… as well as his BIG prediction for June 22nd.
Get the details NOW.